Iroko Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Iroko Pharmaceuticals LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2798
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Iroko Pharmaceuticals LLC (Iroko) is a pharmaceutical company that develops treatment options for responsible pain management. The company’s products comprise low dose Nonsteroidal anti-inflammatory drugs such as meloxicam, indomethacin, and diclofenac that are in various stages of nonclinical and clinical development. It offers products in capsules and tablets dosage forms. Iroko utilizes SoluMatrix fine particle technology to produce NSAIDs as submicron particles. The company conducts research in advancing the science of analgesia in the areas of pain management. It markets its products in the US and abroad. Iroko is headquartered in Philadelphia, Pennsylvania, the US.

Iroko Pharmaceuticals LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Licensing Agreements 11
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Expands Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Equity Offering 19
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Iroko Pharmaceuticals LLC – Key Competitors 21
Iroko Pharmaceuticals LLC – Key Employees 22
Iroko Pharmaceuticals LLC – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Key Facts 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Deals By Therapy Area, 2012 to YTD 2018 8
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Iroko Pharma To Raise US$75 Million In Venture Financing 10
Iroko Pharma Enters into Licensing Agreement with Laboratorios Saval 11
Iroko Pharma Enters into Licensing Agreement with Litha Pharma for ZORVOLEX 12
Iroko Pharma Enters into Licensing Agreement with Aspen Pharma for Zorvolex 13
Iroko Pharma Enters into Licensing Agreement with Landsteiner Scientific for Zorvolex 14
Iroko Pharma Expands Licensing Agreement with Calox for Zorvolex 15
Iroko Pharma Enters into Licensing Agreement with EMS for Zorvolex 16
Iroko Pharma Enters Licensing Agreement With Algorithm For Zorvolex Capsules 17
Iroko Pharma Enters Licensing Agreement With Fahrenheit For Zorvolex Capsules 18
Iroko Pharma Withdraws IPO Of Shares For Up To US$145 Million 19
Iroko Pharmaceuticals LLC, Key Competitors 21
Iroko Pharmaceuticals LLC, Key Employees 22

List of Figures
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Iroko Pharmaceuticals LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Iroko Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • G&W Electric Co:企業の戦略的SWOT分析
    G&W Electric Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Medical Depot Inc:医療機器:M&Aディール及び事業提携情報
    Summary Medical Depot Inc (Drive Medical) is a manufacturer and distributor of durable medical equipment. The company provides rollators, walkers, canes and crutches, commodes, bath safety, patient room , wheelchairs, power mobility, beds, pressure prevention, electrotherapy, lifestyle essentials, r …
  • nLife Therapeutics SL:製薬・医療:M&Aディール及び事業提携情報
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops cell specific oligonucleotides as therapeutic agents for the treatment of central nervous system and neuromuscular disorders. The company’s lead candidate includes NLF-PD-1233, an oligonucle …
  • JFE Holdings Inc (5411):企業の財務・戦略的SWOT分析
    JFE Holdings Inc (5411) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Duke Energy Indiana LLC:企業の戦略的SWOT分析
    Duke Energy Indiana LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • HCA Healthcare Inc (HCA)-製薬・医療分野:企業M&A・提携分析
    Summary HCA Healthcare Inc (HCA), formerly known as HCA Holdings Inc, is a health care services company that provides a wide range of services in specialties including internal medicine; general surgery, cardiology, oncology, neurosurgery, orthopedics and obstetrics. It also offers outpatient and an …
  • NII Holdings, Inc.:戦略・SWOT・企業財務分析
    NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary NII Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Latvenergo AS:企業の戦略的SWOT分析
    Latvenergo AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Bafna Pharmaceuticals Ltd (BAFNAPHARM):企業の財務・戦略的SWOT分析
    Summary Bafna Pharmaceuticals Ltd (Bafna Pharmaceuticals) is a pharmaceutical company that manufactures and markets medicinal products. The company provides operations such as domestic marketing, international marketing, international export and business development, among others. It offers products …
  • Fortescue Metals Group Ltd:企業のM&A・事業提携・投資動向
    Fortescue Metals Group Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Fortescue Metals Group Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Motiva Enterprises LLC:企業の戦略・SWOT・財務情報
    Motiva Enterprises LLC - Strategy, SWOT and Corporate Finance Report Summary Motiva Enterprises LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Delaware North Companies Inc:企業の戦略的SWOT分析
    Delaware North Companies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Omega Pharma NV-製薬・医療分野:企業M&A・提携分析
    Summary Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company's product portfolio includes cough and cold product …
  • Peace River Electric Cooperative, Inc.:企業の発電所・SWOT分析2018
    Peace River Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informati …
  • CMA CGM SA:企業のM&A・事業提携・投資動向
    CMA CGM SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CMA CGM SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Permian Basin Royalty Trust (PBT):企業の財務・戦略的SWOT分析
    Summary Permian Basin Royalty Trust (Permian Basin Royalty) is an oil and gas company that owns overriding royalty rights in mineral properties in the US. The company provides oil and gas products. It has assets comprises of 75 percent net overriding royalty interest in the Waddell Ranch Properties …
  • Magyar Nemzeti Bank:企業の戦略的SWOT分析
    Magyar Nemzeti Bank - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • RHÖN-KLINIKUM AG:企業の戦略・SWOT・財務情報
    RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report Summary RHÖN-KLINIKUM AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • The Economist Group Ltd:企業の戦略的SWOT分析
    The Economist Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • MAPFRE RE, Compania de Reaseguros S.A.:企業の戦略・SWOT・財務情報
    MAPFRE RE, Compania de Reaseguros S.A. - Strategy, SWOT and Corporate Finance Report Summary MAPFRE RE, Compania de Reaseguros S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆